SCHEMBL4927632

SCHEMBL4927632

NC(=O)C1CCCN1C(=O)c1ccccn1

nearest known ligand 0.53

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.53
SCN9A Q15858 1/20 0.52
CNR2 P34972 5/20 0.50
VNN1 O95497 1/20 0.49
SPHK2 Q9NRA0 1/20 0.48
SPHK1 Q9NYA1 1/20 0.48
EPHX2 P34913 1/20 0.47
DGAT1 O75907 2/20 0.46
PDK2 Q15119 1/20 0.45
GRM5 P41594 2/20 0.45
SCD5 Q86SK9 1/20 0.44
CHRNB2 P17787 1/20 0.44
CHRNB4 P30926 1/20 0.44
CHRNA3 P32297 1/20 0.44
CHRNA7 P36544 1/20 0.44
CHRNA4 P43681 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4927636 1.00 L3MBTL1 (0.53) L3MBTL1SCN9ACNR2VNN1SPHK2
SCHEMBL3168169 0.87 DGAT1 (0.58) L3MBTL1EPHX2DGAT1SCD5
SCHEMBL3168186 0.87 DGAT1 (0.58) L3MBTL1EPHX2DGAT1SCD5
SCHEMBL25793395 0.86 L3MBTL1 (0.53) L3MBTL1EPHX2DGAT1GRM5SCD5
SCHEMBL25793389 0.86 L3MBTL1 (0.53) L3MBTL1EPHX2DGAT1GRM5SCD5
SCHEMBL4924222 0.84 L3MBTL1 (0.50) L3MBTL1EPHX2DGAT1GRM5SCD5
SCHEMBL4924225 0.84 L3MBTL1 (0.50) L3MBTL1EPHX2DGAT1GRM5SCD5
SCHEMBL3175587 0.83 DGAT1 (0.54) L3MBTL1EPHX2DGAT1GRM5
SCHEMBL3178325 0.83 DGAT1 (0.54) L3MBTL1EPHX2DGAT1GRM5
SCHEMBL3178211 0.83 DGAT1 (0.54) L3MBTL1EPHX2DGAT1GRM5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080269282-A1 Compounds for Inhibiting Copper-Containing Amine Oxidases and Uses Thereof GENMEDICA THERAPEUTICS SL (ES) 2008-10-30 US disclosed
EP-1796681-A2 COMPOUNDS FOR INHIBITING COPPER-CONTAINING AMINE OXIDASES AND USES THEREOF Genmedica Therapeutics SL (ES) 2007-06-20 EP disclosed
US-20070066646-A1 Compounds for Inhibiting Copper-Containing Amine Oxidases and Uses Thereof GENMEDICA THERAPEUTICS SL (ES) 2007-03-22 US disclosed
WO-2006013209-A2 COMPOUNDS FOR INHIBITING COPPER-CONTAINING AMINE OXIDASES AND USES THEREOF GENMEDICA THERAPEUTICS SL (ES) 2006-02-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080269282-A1 Compounds for Inhibiting Copper-Containing Amine Oxidases and Uses Thereof AOC2, AOC3, AOC1 L3MBTL1 2228/4885SCN9A 1274/4885CNR2 4335/4885
US-20070066646-A1 Compounds for Inhibiting Copper-Containing Amine Oxidases and Uses Thereof AOC2, AOC3, AOC1 L3MBTL1 2083/4885SCN9A 1214/4885CNR2 4342/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.